A new antiviral targeting the hepatitis B virus capsid protein
Official title: A new class of antiviral directed at HBV capsid protein
Funded at Door Pharmaceuticals, LLC · NIH-10816889 · Data updated 2026-11-12
This study is testing a new treatment for people with chronic Hepatitis B that aims to better target the virus while reducing side effects, making it a potentially more effective option for managing the condition.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Door Pharmaceuticals, LLC NIH-funded |
| Lab location | 1 site (Bloomington, United States) |
| Project start | January 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $306,500 |
| NIH project number | 1R43AI181057-01 |
| Project ID | NIH-10816889 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with chronic hepatitis B virus infection.
✕Less likely to help
Patients who have not been diagnosed with chronic hepatitis B or those with acute hepatitis B may not benefit from this research.
What this research studies
This research focuses on developing a novel antiviral treatment for chronic Hepatitis B Virus (HBV) by targeting the virus's capsid protein. The approach involves creating reactive capsid assembly modulators (rCAMs) that can specifically bind to viral nucleic acids, enhancing the effectiveness of the treatment while minimizing side effects. By concentrating the reactive components near the viral DNA and RNA, this method aims to provide a more effective and potentially curative therapy for patients suffering from chronic HBV. The research is being conducted by Door Pharmaceuticals, which has a strong background in this area.
Why it matters
Potential benefit: If successful, this research could lead to a curative treatment for chronic hepatitis B, significantly improving patient outcomes.
How similar studies have gone: While the approach of using capsid assembly modulators is innovative, similar strategies targeting viral components have shown promise in other viral infections, indicating potential for success.
Where this research is happening
-
Door Pharmaceuticals, LLC
Bloomington, United States Active
Researchers
- Principal investigator: Nair, Smita — Door Pharmaceuticals, LLC
- Study coordinator: Nair, Smita
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.